18 recruiting, 11 unknown, 7 terminated, 6 not yet recruiting. 23 Phase 1, 14 Phase 2, 8 Not applicable, 4 Phase 3.
Follow AML, Adult: new trials by email Literature Review of AML, Adult trials Research Report on AML, Adult
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| VAG Versus Standard Chemotherapy With FLT3 Inhibitor in Adult Patients With FLT3-Mutated AML Gilteritinib + Azacitidine + Venetoclax, Cytarabine + Daunorubicin (or Idarubicin) + Gilteritinib, Re-induction Therapy - AML, Adult | Phase 3 | Not yet recruiting | Institute of Hematology & Blood Diseases Hospital, China | 300 | 2026-04-30 | 2026-03-25 |
| Quality of Life-Guided Transfusion in Refractory MDS or AML Red blood cell transfusions based on EQ-5D-5L questionnaire - MDS, AML, Adult | Not applicable | Recruiting | Centre Hospitalier Universitaire de Nice | 52 | 2026-02-09 | 2026-02-12 |
| Comparison of VA and D/IA Induction Regimens in Elderly Fit Acute Myeloid Leukemia Patients Daunorubicin/Idarubicin, Cytarabine, Azacitidine - AML, Adult | Phase 3 | Recruiting | Institute of Hematology & Blood Diseases Hospital, China | 240 | 2025-08-31 | 2026-03-02 |
| Observational Study on the Outcome of AML Patients Treated With New Drugs in Real-life (BoxTrial) Acute Myeloid Leukemia, AML, Adult | Recruiting | Gruppo Italiano Malattie EMatologiche dell'Adulto | 397 | 2025-07-11 | 2025-08-13 | |
| Eganelisib as Monotherapy and in Combination With Cytarabine in Relapsed/Refractory AML/HR-MDS and in Combination With Azacitidine in Previously Untreated HR-MDS Eganelisib, Eganelisib in combination with cytarabine, Eganelisib in combination with azacitidine - AML, Adult, MDS | Phase 1 | Recruiting | Stelexis BioSciences | 105 | 2025-04-28 | 2026-10-20 |
| Study of Tretinoin Capsules in Combination With Azacitidine and Venetoclax in Treatment Naïve Participants With Acute Myeloid Leukemia ATRA+Venetoclax+Azacitidine, Chemotherapy drug - AML, Adult | Not applicable | Not yet recruiting | The First Affiliated Hospital of Soochow University | 158 | 2025-02-15 | 2025-02-24 |
| Avapritinib Maintenance for AML With KIT Mutations Avapritinib - AML, Adult | Phase 2 | Not yet recruiting | Ruijin Hospital | 47 | 2025-02-01 | 2025-01-09 |
| Venetoclax-Decitabine in Untreated Elderly/Unfit AML VEN + DEC - AML, Adult | Not applicable | Recruiting | The Second Hospital of Hebei Medical University | 39 | 2025-01-17 | 2025-08-12 |
| Selinexor Combined With Venetoclax Maintenance Therapy After Allo-HSCT selinexor in combination with venetoclax - MDS, AML, Adult | Phase 2 | Not yet recruiting | Ruijin Hospital | 73 | 2025-01-01 | 2025-01-09 |
| Revumenib in Combination With 7+3 + Midostaurin in AML Revumenib, Midostaurin, Cytarabine - Acute Myeloid Leukemia, AML, Adult | Phase 1 | Recruiting | Richard Stone, MD | 22 | 2024-12-06 | 2026-03-25 |
| Pharmacoscopy-guided Clinical Standard-of-care in r/r AML Pharmacoscopy, Clinical standard-of-care (physician's choice) - AML, Adult | Phase 2 | Unknown | ETH Zurich | 88 | 2024-09-02 | 2025-05-16 |
| OBServatory of Compassionate Use of IVOsidenib in France for Patients With Acute Myeloid Leukemia AML, Adult | Recruiting | French Innovative Leukemia Organisation | 250 | 2024-07-31 | 2025-11-26 | |
| Sequential CAR-T Cells Targeting CD33/CD123 in Patients With Acute Myelocytic Leukemia AML CD123/CD33 CART - AML, Acute Myeloid Leukemia | Phase 1 / Phase 2 | Recruiting | Essen Biotech | 85 | 2024-07-10 | 2024-11-12 |
| Results From a French Temporary Utilization Authorization of First-line Acute Myeloid Leukemia (AML) Patients Ineligible for Intensive Chemotherapy (IC), Treated With Venetoclax Azacitidine AML, Adult | Unknown | French Innovative Leukemia Organisation | 230 | 2024-07-04 | 2024-07-23 | |
| Kinetics and Impact on Survival of MRD in AML Patients Receiving Azacitidine and Venetoclax MRD assessment - AML, Adult, Minimal Residual Disease | Not applicable | Not yet recruiting | Gruppo Italiano Malattie EMatologiche dell'Adulto | 225 | 2024-07-01 | 2024-04-10 |
| Compare the Efficacy and Safety of Dec-FB4 and FB4 as Conditioning Regimen for AML-MR Decitabine, Fludarabine Injection, Busulfan Injection - AML, Adult | Phase 3 | Not yet recruiting | Ruijin Hospital | 220 | 2024-06-01 | 2024-06-04 |
| D-index as a Predictor of Complication of Treatment of Patients With Acute Myeloid Leukemia AML, Adult | Unknown | Assiut University | 60 | 2024-06-01 | 2024-01-03 | |
| MRD-positive AML Clinical Study Ivosidenib, Gilteritinib, Venetoclax - AML, Adult | Not applicable | Recruiting | Institute of Hematology & Blood Diseases Hospital, China | 537 | 2024-05-11 | 2026-08-10 |
| Natural Killer(NK) Cell Therapy Targeting CLL1 or CD33 in Acute Myeloid Leukemia iPSC-NK cells - AML, Adult | Phase 1 | Unknown | Zhejiang University | 24 | 2024-04-30 | 2024-04-18 |
| A Trial to Assess Cobicistat Boosted Venetoclax in Combination With Azacitidine in Adult Patients With Newly Diagnosed AML azacitidine, Venetoclax, Cobicistat - AML, Adult | Phase 2 | Recruiting | Stichting Hemato-Oncologie voor Volwassenen Nederland | 142 | 2024-01-17 | 2026-09-23 |
Showing 20 of 53. Sign in to see all of them.
Leukemia, Myeloid, Acute (53) · Myelodysplastic Syndromes (4) · Neoplasm, Residual (4) · Leukemia (3) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (3) · Recurrence (3) · Anemia (1) · Leukemia, Lymphocytic, Chronic, B-Cell (1) · Multiple Myeloma (1) · Neoplasms, Plasma Cell (1)
Hematologic Diseases (53) · Hemic and Lymphatic Diseases (53) · Leukemia, Myeloid (53) · Neoplasms (53) · Neoplasms by Histologic Type (53) · Leukemia (50) · Pathologic Processes (7) · Pathological Conditions, Signs and Symptoms (7) · Immune System Diseases (5) · Immunoproliferative Disorders (5) · Lymphoproliferative Disorders (5) · Bone Marrow Diseases (4) · Leukemia, Lymphoid (4) · Lymphatic Diseases (4) · Neoplastic Processes (4)
Azacitidine (12) · Cytarabine (11) · venetoclax (11) · fludarabine (8) · Cyclophosphamide (6) · Daunorubicin (4) · Idarubicin (4) · gilteritinib (4) · Decitabine (3) · Etoposide (2) · avapritinib (2) · midostaurin (2) · selinexor (2) · ALX148 (1) · Busulfan (1)
Institute of Hematology & Blood Diseases Hospital, China (5) · French Innovative Leukemia Organisation (4) · Gruppo Italiano Malattie EMatologiche dell'Adulto (4) · Zhejiang University (4) · Ruijin Hospital (3) · BioSight Ltd. (2) · ALX Oncology Inc. (1) · Abramson Cancer Center at Penn Medicine (1) · Ascentage Pharma Group Inc. (1) · Assiut University (1) · Celyad Oncology SA (1) · Centre Hospitalier Universitaire de Nice (1) · Chen Suning (1) · Cyclacel Pharmaceuticals, Inc. (1) · ETH Zurich (1)
China (20) · United States (16) · France (5) · Italy (3) · Switzerland (2) · Australia (1) · Netherlands (1) · Norway (1) · Spain (1)
He Huang, MD (2) · Alexandre Theocharides, MD PhD (1) · Anders Erik Astrup Dahm, MD, PHD (1) · Anna Candoni (1) · Antonio Curti (1) · Arnaud Pigneux, Prof (1) · Bei Liu, Dr. (1) · Catherine Lai, MD (1) · David Shook, MD (1) · Dengju Li, Prof. (1) · Depei WU, Prof. (1) · Elizabeth Brem, MD (1) · Fei Li, Prof. (1) · Frederic Lehmann, MD (1)
PMID 17019734, PMID 19597026, PMID 21205990, PMID 34215207, PMID 35892511, PMID 36660358, PMID 36841672, PMID 36892565, PMID 37216345, PMID 38502195, PMID 40009498, PMID 40668612, PMID 41748936, PMID 42007248, PMID 42439986
2023 (1)